Viavi Solutions Inc (Viavi) provides network test, monitoring, and assurance solutions. It offers 3D sensing avionics test contractors, custom optics, enterprise fiber, high-speed networks, land mobile, and military radio wireless solutions. The company serves communications service providers and enterprises. It offers light management solutions to anti-counterfeiting, consumer and industrial, government and healthcare, and other markets. VIAVI also empowers network operators, equipment manufacturers, government, aerospace, and railways with intuitive instruments, intelligence, and insights.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Viavi’s research and development strategy centers on creating new products, upgrading existing lines, and optimizing manufacturing efficiency and product performance. The company’s portfolio includes portable test instruments, software, and systems designed for Network Operations Centers, alongside specialized equipment used to develop, test, and manufacture communications network components. Additionally, its MicroNIR product line features compact near-infrared (NIR) spectrometers that deliver benchtop-level performance to support process development from lab research through full-scale production. To deliver comprehensive, turn-key solutions, the company provides model transfer services and a software development kit compatible with multiple interfaces, including smartphones and tablets. Viavi holds a robust intellectual property portfolio consisting of roughly 1,220 U.S. patents, 2,225 foreign patents, and 1,062 pending patent applications. In FY2026, the company incurred expenses of US$262.7 million on R&D, which as a percentage of revenue, stood at 17.3%.